TP53 and myelodysplastic syndrome: ICC 2022 recognizes the following MDS-defining cytogenetic abnormalities, irrespective of dysplasia, in the context of persistent cytopenia: del(5q), multi-hit TP53 mutation, and −7/del(7q) and complex karyotype (>3 unrelated clonal chromosomal abnormalities in the absence of other class-defining recurring genetic abnormalities), which are classified as MDS with del(5q), MDS with mutated TP53, or MDS, not otherwise specified (MDS, NOS), respectively.